Turn Therapeutics Inc. (TTRX)
| Market Cap | 271.67M |
| Revenue (ttm) | n/a |
| Net Income | -3.84M |
| EPS | -0.14 |
| Shares Out | 29.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 104,521 |
| Open | 8.88 |
| Previous Close | 9.03 |
| Day's Range | 8.51 - 9.45 |
| 52-Week Range | 2.57 - 26.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 10, 2026 |
About TTRX
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeu... [Read more]
Financial Performance
Financial StatementsNews
Turn Therapeutics Transcript: Study update
GX-03 phase II trial for atopic dermatitis advances to an optimized stage two after interim analysis showed strong efficacy and safety, especially in patients with higher pruritus scores. The study uses a stratified, adaptive design and targets a phase II readout in Q4 2026.
Turn Therapeutics Press release: Study update
Turn Therapeutics issued a press release on July 7, 2026, disclosing material business information to investors.
Turn Therapeutics Slides: Study update
Turn Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Turn Therapeutics announces final Stage 2 design of atopic dermatitis program
Turn Therapeutics (TTRX)announced the completion of a comprehensive interim analysis of its ongoing adaptive Phase 2 clinical trial evaluating GX-03 for the treatment of atopic dermatitis. The multi-w...
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, to...
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, to...
Turn Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
GX-03, a novel topical therapy, demonstrated strong efficacy and safety in phase II eczema trials, with rapid onset and no adverse events. The company is expanding into toenail fungus and other inflammatory indications, supported by robust IP, a lean operation, and a strong leadership team.
Turn announces interim analysis findings from Phase 2 trial of GX-03
Turn Therapeutics (TTRX) announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled Phase 2 clinical trial evaluating...
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today ...
Turn Therapeutics announces peer-reviewed article on GX-03
Turn Therapeutics (TTRX) announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the effects of its lead program, GX-03, in an IL-36-associa...
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin ...
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today ...
Turn appoints Hahn as Executive Clinical, Regulatory Lead for GX-03
Turn Therapeutics (TTRX) announced the appointment of Stephen Hahn, M.D., former Commissioner of the U.S. Food and Drug Administration, FDA, to oversee the clinical and regulatory strategy for GX-03, ...
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today ...
Turn Therapeutics reports Q1 EPS (3c) vs. (1c) last year
Cash and cash equivalents as of March 31, 2026 were $11.2 million as compared to $5.08 million as of December 31, 2025. “The first quarter of 2026 materially strengthened Turn…
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic c...
Turn Therapeutics Earnings release: Q1 2026
Turn Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Turn Therapeutics Quarterly report: Q1 2026
Turn Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Turn Therapeutics Slides: Corporate presentation
Turn Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Turn Therapeutics reports FY25 EPS (12c) vs. (7c) last year
“Our first months as a public company have been highly productive, with strong progress across our clinical, financial, and strategic priorities,” said Bradley Burnam, Chief Executive Officer of Turn ...
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today...
Turn Therapeutics Annual report: Q4 2025
Turn Therapeutics has published its Q4 2025 annual report on March 31, 2026.
Turn Therapeutics Earnings release: Q4 2025
Turn Therapeutics released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Turn Therapeutics secures up to $25M in financing
Turn Therapeutics (TTRX) entered into a growth capital loan facility with Avenue Venture Opportunities Fund II for up to $25M. The facility includes an initial $7M tranche funded at closing,…
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered int...